How Wegovy works in the body: the science behind the weight loss

The myth worth correcting first: Wegovy is not a metabolism booster

The most persistent misconception is that Wegovy speeds up your metabolism or burns fat directly. It does neither. Semaglutide does not increase your calorie expenditure at rest, and it does not instruct fat cells to release stored energy. What it does is act on the biology of appetite and satiety in a way that makes a calorie deficit much easier to sustain over months, rather than days.

The weight loss comes from eating less. The medicine makes eating less the path of least resistance, rather than a daily act of self-denial. That distinction matters because it explains why the effect takes several weeks to build, why missing doses matters, and why the titration schedule exists, the body needs time to adapt to each new level before the full appetite-suppressing benefit settles in. Our semaglutide overview covers the broader clinical picture if you want the wider context.

It also explains why Wegovy is not a quick fix and why the MHRA explicitly states these medicines are not assessed for cosmetic weight loss. The licensed use is medical weight management, alongside a reduced-calorie diet and increased physical activity.

The GLP-1 pathway: what the hormone actually does

GLP-1 stands for glucagon-like peptide-1. Your gut secretes it after a meal, and it does several things at once. It signals to the hypothalamus (the part of the brain that governs hunger) that food has arrived and appetite should fall. It slows gastric emptying, so food sits in the stomach longer and fullness is sustained. It also stimulates insulin release and suppresses glucagon in response to blood glucose, which is why semaglutide was originally developed for type 2 diabetes before the weight-management data emerged.

Semaglutide is a synthetic analogue of GLP-1, engineered to resist breakdown so it lasts in the body for roughly seven days, hence the once-weekly injection. Natural GLP-1 is cleared within minutes. The prolonged action means the appetite signal is sustained throughout the week rather than peaking after meals and vanishing. A closer look at what semaglutide does to the body goes deeper on the receptor-level mechanism for readers who want it.

The NHS medicine page for semaglutide explains this pathway in plain language and lists the full side-effect profile, it is the right first stop for anyone wanting the patient-level picture from a UK clinical source.

What the trial evidence actually showed, and what it did not

The STEP 1 trial, published in the New England Journal of Medicine, randomised 1,961 adults with obesity to semaglutide 2.4 mg or placebo over 68 weeks, alongside lifestyle support. Average weight reduction in the semaglutide group was around 15% of starting body weight. That is a meaningful clinical result, enough to reduce blood pressure, improve cholesterol, lower the risk of sleep apnoea worsening, and ease joint load. Our Wegovy page covers the full evidence picture and what results tend to look like in real use.

What the trial did not show: that everyone responds equally, or that results persist indefinitely without continued treatment. Weight tends to return if the medicine is stopped and lifestyle support is withdrawn. That is not a flaw unique to semaglutide, it reflects the biology of obesity as a chronic condition rather than a one-time problem to solve. A prescriber's job is partly to help you understand this before you start, so expectations are realistic from week one.

One practical note: the titration schedule starts at 0.25 mg and moves upward roughly every four weeks. Many people find the nausea that can accompany the early weeks is at its worst around dose changes, then settles. If you are curious about how Wegovy works in your body at each stage of the titration, that detail can help you make sense of what you are experiencing as doses increase. Exact timing, missed doses, and any changes to your schedule should always be discussed with your prescriber rather than adjusted independently. The FAQs page addresses common practical questions.

Who can access Wegovy, and what the prescription process involves

Wegovy is licensed in the UK for adults with a BMI of 30 or above, or from 27 if at least one weight-related condition is present, for example high blood pressure, high cholesterol, prediabetes, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. Holding a qualifying BMI is a starting point; the prescriber assesses the whole picture, including other medicines you take and your medical history, before deciding whether Wegovy is appropriate.

On the NHS, access is via specialist weight management services under NICE guidance (TA875), and waiting lists in many areas are long. Private treatment through a regulated pharmacy is the alternative for people who do not meet current NHS criteria or who prefer not to wait. If you want an honest account of how Wegovy works in the body before deciding whether to proceed, reading that alongside the costs and process gives you the clearest starting point. At nume, every consultation is reviewed by a GPhC-registered Independent Prescriber, a real clinician reads your answers the same day, not software.

If after reading all of this you think Wegovy may be right for you, the next step is a clinical conversation. Many people find it helpful to read about how Wegovy works before starting that conversation, so they can ask more informed questions. Check your eligibility by starting your free consultation with our prescribing team.